Arctis Global’s Iovance Biotherapeutics IOVA Stock Holding History

Arctis Global’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-87,331	Closed	-$397K	–	7
2023 Q3	$397K	Buy	+87,331	New	+$570K	0.21%	13

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Arctis Global's IOVA Position: Q4 2023 in Review

Arctis Global sold out of Iovance Biotherapeutics (IOVA) in Q4 2023, closing a stake of 87,331 shares — an estimated $397K sold.

Arctis Global first reported a position in IOVA in Q3 2023 and held it in 1 quarter. The position peaked at $397K in Q3 2023. 236 funds tracked by Wall St. Rank hold IOVA as of Q4 2023.

Arctis Global reported no remaining Iovance Biotherapeutics position as of Q4 2023 after selling out during the quarter.
Arctis Global sold 87,331 Iovance Biotherapeutics shares in Q4 2023, an estimated $397K.
Arctis Global first reported a position in Iovance Biotherapeutics in Q3 2023 and held it in 1 quarter.
Arctis Global's Iovance Biotherapeutics position peaked at $397K in Q3 2023.
236 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2023.

Based on Arctis Global's 13F filing for Q4 2023, filed 14 Feb 2024.